Displaying drugs 3476 - 3500 of 11305 in total
Echinacea angustifolia root
Approved
Experimental
Etafedrine
Etafedrine (INN) or ethylephedrine is a long-acting bronchodilator and has been an ingredient combined with other drugs in the brand names Nethaprin and Dalmacol . It was previously available as both the free base and as the hydrochloride salt manufactured by Sanofi-Aventis (now Sanofi) has been discontinued .
Ethylephedrine is...
Approved
Matched Description: … Etafedrine (INN) or ethylephedrine is a long-acting bronchodilator and has been an ingredient combined ... The hydrochloride is be prepared by passing hydrogen chloride through a solution of ethylephedrine in …
Bird pepper
Bird pepper is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Approved
Experimental
Matched Description: … Bird pepper is a plant/plant extract used in some OTC (over-the-counter) products. …
Glasdegib
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds...
Approved
Investigational
Matched Description: … Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under ... In early research, benzimidazoles attracted large interest as they represented a class of inhibitors ... the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a …
Lincomycin
Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.[A190657, A190621]
Lincomycin was approved...
Approved
Vet approved
Matched Description: … Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium _Streptomyces lincolnensis ... largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a …
Siltuximab
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment...
Approved
Investigational
Matched Description: … Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese ... It is administered as a 1 hour intravenous infusion every 3 weeks. ... MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and …
Omalizumab
Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). IgE promotes the release of inflammatory mediators from mast cells and basophils during allergic and inflammatory reactions. By binding to IgE and neutralizing it, omalizumab reduces free IgE levels and prevents IgE from binding to its...
Approved
Investigational
Matched Description: … Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin ... [L50482] It is used to treat a range of immune and inflammatory conditions, including allergies, urticaria …
Lenalidomide
Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of thalidomide and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with...
Approved
Matched Description: … exists as a racemic mixture of the active S(-) and R(+) forms. ... [A228553] It is a 4-amino-glutamyl analogue of [thalidomide] [A228543] and like thalidomide, lenalidomide ... lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a …
Fosnetupitant
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form...
Approved
Matched Description: … Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality ... Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a …
Caplacizumab
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy...
Approved
Investigational
Matched Description: … of two identical humanized building blocks genetically linked by a three-alanine linker. ... Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting ... Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and …
Delamanid
Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall . It is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. Emergence of multidrug-resistant and extensively drug-resistant tuberculosis creates clinical challenges for...
Approved
Investigational
Matched Description: … is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a ... In a clinical study involving patients with pulmonary multidrug-resistant tuberculosis or extensively ... drug-resistant tuberculosis creates clinical challenges for patients, as the disease is associated with a …
Cefoperazone
Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its...
Approved
Investigational
Matched Description: … Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas ... It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections …
Liraglutide
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid...
Approved
Matched Description: … a GLP-1 receptor agonist. ... [A6932] Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer ... Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as …
Artemisia douglasiana pollen
Artemisia douglasiana pollen is the pollen of the Artemisia douglasiana plant. Artemisia douglasiana pollen is mainly used in allergenic testing.
Approved
Arrhenatherum elatius pollen
Arrhenatherum elatius pollen is the pollen of the Arrhenatherum elatius plant. Arrhenatherum elatius pollen is mainly used in allergenic testing.
Approved
Artemisia dracunculus pollen
Artemisia dracunculus pollen is the pollen of the Artemisia dracunculus plant. Artemisia dracunculus pollen is mainly used in allergenic testing.
Approved
Practolol
A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.
Approved
Matched Description: … A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias. …
Tarlatamab
Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer. It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed across various SCLC disease stages...
Approved
Investigational
Matched Description: … Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer. ... [L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells …
Pertuzumab
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in...
Approved
Matched Description: … Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization ... Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant …
Camponotus pennsylvanicus
Camponotus pennsylvanicus allergenic extract is used in allergenic testing.
Approved
Panitumumab
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
Approved
Investigational
Matched Description: … Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the …
Elexacaftor
Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with tezacaftor and ivacaftor as the combination product TrikaftaTM. Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure...
Approved
Investigational
Matched Description: … [L9395] Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure ... Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis ... A187361] While dual corrector/potentiator combination therapy has proven useful in the treatment of a …
Displaying drugs 3476 - 3500 of 11305 in total